Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.030
+0.035 (0.88%)
At close: Feb 6, 2026, 4:00 PM EST
3.945
-0.085 (-2.11%)
After-hours: Feb 6, 2026, 5:05 PM EST

Neuphoria Therapeutics Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Revenue
15.6515.65--0.18-
Other Revenue
----3.990.7
15.6515.65--4.170.7
Revenue Growth (YoY)
----499.60%-66.32%
Cost of Revenue
----11.024.32
Gross Profit
15.6515.65---6.85-3.62
Selling, General & Admin
7.977.778.478.915.284.23
Research & Development
10.598.719.3212.65--
Other Operating Expenses
-----0-0.15
Operating Expenses
18.5616.4817.821.565.274.08
Operating Income
-2.91-0.83-17.8-21.56-12.12-7.7
Interest Expense
-----0.02-1.07
Interest & Investment Income
0.270.170.220.320.010
Currency Exchange Gain (Loss)
-0.2-0.41-0.210.310.250.81
Other Non Operating Income (Expenses)
-7.24----2.59-1.22
EBT Excluding Unusual Items
-10.08-1.08-17.79-20.93-14.48-9.18
Gain (Loss) on Sale of Investments
0.240.242.21-0.59--
Gain (Loss) on Sale of Assets
-----0-0.02
Other Unusual Items
-----0.652.54
Pretax Income
-9.84-0.84-15.58-21.52-15.12-6.66
Income Tax Expense
-0.37-0.47-0.09-0.14-0.13-0.14
Earnings From Continuing Operations
-9.47-0.37-15.49-21.38-14.99-6.52
Net Income
-9.47-0.37-15.49-21.38-14.99-6.52
Net Income to Common
-9.47-0.37-15.49-21.38-14.99-6.52
Shares Outstanding (Basic)
2211,4691,353780
Shares Outstanding (Diluted)
2211,4691,353780
Shares Change (YoY)
-99.94%95.01%-99.94%8.53%73.52%43.14%
EPS (Basic)
-5.09-0.23-18.62-0.01-0.01-0.01
EPS (Diluted)
-5.09-0.23-18.62-0.01-0.01-0.01
Free Cash Flow
0.720.08-14.68-14.64-14.99-5.65
Free Cash Flow Per Share
0.390.05-17.64-0.01-0.01-0.01
Gross Margin
100.00%100.00%---164.21%-
Operating Margin
-18.62%-5.30%---290.62%-1107.29%
Profit Margin
-60.52%-2.36%---359.34%-937.11%
Free Cash Flow Margin
4.57%0.49%---359.30%-812.46%
EBITDA
-2.25-0.17-17.13-20.9-11.49-7
EBITDA Margin
-14.38%-1.06%---275.36%-
D&A For EBITDA
0.660.660.660.660.640.7
EBIT
-2.91-0.83-17.8-21.56-12.12-7.7
EBIT Margin
-18.62%-5.30%---290.62%-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q